Rafael Fonseca, M.D.

Rafael Fonseca, M.D.

The laboratory of Rafael Fonseca, M.D., concentrates on the genetic and cytogenetic nature of the clonal cells of the plasma cell disorders.

To achieve this, Dr. Fonseca's lab uses a variety of tools, including next-generation sequencing, single-cell analysis molecular genetics, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), gene expression profiling, array-based comparative genomic hybridization (aCGH) and others. The laboratory is currently composed of five full-time technologists and three postdoctoral fellows.

 

Laura Jean Esserman, M.D., MBA

Laura Jean Esserman, M.D., MBA

Dr. Esserman is a surgeon and breast cancer oncology specialist, and is the Director of the Carol Franc Buck Breast Care Center at the University of California, San Francisco (UCSF).  In 1996, she started the Center of Excellence for Breast Cancer Care to integrate clinical care and research, automate tools for the capture of patient and clinical data, and develop systems to tailor care to biology, patient preference, and performance.  She is nationally and internationally recognized leader in the field of breast cancer and has published over 200 peer reviewed publications.

David Duggan, Ph.D.

David Duggan, Ph.D.

Dr. Duggan is a graduate of the University of Pittsburgh with a doctorate degree in human genetics. He did his post‐doctoral studies at the National Human Genome Research Institute (NHGRI, National Institutes of Health, Bethesda, MD, USA) and later moved to an Associate Investigator position at the National Institute of Arthritis and Muscoloskeletal and Skin Diseases before relocating his laboratory to TGen in 2003.

Eslie Dennis, M.D.

Eslie Dennis, M.D.

Dr. Eslie Dennis is a physician with 10 years’ experience in clinical practice (internal medicine and hematology/oncology), 1+ years’ laboratory research (immunology/tuberculosis), 16 years’ international experience in the biopharmaceutical industry, and 2+ years’ leadership experience in non-profit public-private partnerships.

Carolyn Compton, M.D., Ph.D.

Carolyn Compton, M.D., Ph.D.

Carolyn Compton, M.D., Ph.D., is an academic pathologist specializing in gastrointestinal disease and is board certified in both anatomic and clinical pathology.  She is a Professor at Arizona State University and an Adjunct Professor of Pathology at both the University of Arizona and Johns Hopkins. At ASU she is on the faculty of the School of Life Sciences and at Mayo Clinic, she is a Research Affiliate in the Department of Pathology and Laboratory Medicine.

Lynda Chin, M.D., Ph.D.

Lynda Chin, M.D., Ph.D.

Dr. Lynda Chin graduated with an M.D. degree from Albert Einstein College of Medicine in 1993 and is a board-certified dermatologist. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine, where she completed in parallel her residency training in the hospital and postdoctoral fellowship in the laboratory.  For the 13 years prior to joining the University of Texas MD Anderson Cancer Center in 2011, Dr.

Xiaohong (Sherry) Cao, Ph.D.

Xiaohong (Sherry) Cao, Ph.D.

Sherry has over ten years’ experience in genomic research and bioinformatics focusing on genomic data analysis for disease and therapeutic biomarker development.  She spearheaded the genomic & informatics efforts for several critical biomarker planning and development projects within Genzyme, a Sanofi company.  Her research interest focuses on using statistical and network analysis approaches for disease targeting and compound repositioning.  She is an out-of-the-box thinker who can connect the dots between clinical and research programs.  Recently, she has been the

Richard E. Buller, MD, PhD

Richard E. Buller, MD, PhD

Richard Buller, M.D, Ph.D was recently appointed as Head of Oncology Clinical Development at Pfizer following three years as Vice President of Translational Oncology. His former group was responsible for development of biomarker and companion diagnostic clinical strategies as well as proof of mechanism/pharmacology for drug candidates.  Recent success is reflected by the approval of crizotinib for the treatment of ALK positive NSCLC. 

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS